Phase I Clinical Trials of Cancer Drug ETS2101 Approved by Regulators
News Mar 29, 2012
e-Therapeutics plc has announced that regulatory agencies in the UK and the US have approved plans for phase I trials of the Company’s anti-cancer drug ETS2101 and that enrolment of patients into trials in these two countries will begin shortly.
A phase I trial in the UK will recruit patients with a variety of solid tumours, while a US investigator-led trial will enrol patients with primary or secondary brain cancers.
Further details of each trial will be provided when its first patient is treated.
Professor Malcolm Young, CEO of e-Therapeutics, said: “We remain on track to report the first data from cancer trials with ETS2101 and to advance three further drugs into the clinic by the end of this year.”
e-Therapeutics’ latest expectations for its other products are that ETX1153c (for C. difficile infection) will start phase I in Q2 or Q3, that ETS6103 (for major depressive disorder) will enter phase IIb in Q3 and that ETX1153a (for MRSA infection) will start phase I in Q4.
Lonza Expands Encapsulation and HPAPI Capabilities in North AmericaNews
Expanding our capabilities into commercial-scale encapsulation responds to our customers' desire to maintain programs at the Tampa, FL (USA) site from clinical development to commercialization.READ MORE
Researchers Discover Key Link Between Mitochondria and Cocaine AddictionNews
Researchers were able to block response in mitochondria to cocaine.READ MORE
Tuberculosis Vaccine Trial Results Offer Potential for BCG RevaccinationNews
The study is the first 'prevention of infection' trial conducted for tuberculosis, the world's leading infectious disease killer.READ MORE
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018